Thus, in this study we demonstrate that small molecule agonists of STING provide long-lasting relief from cancer-induced bone pain via distinct and synergistic actions on pain-sensing nociceptors, adaptive immune cells, and osteoclasts through a mechanism dependent on IFN-I signaling. This evidence concerns the gene STING1 and cancer.